Kenneth R Locke

US Patent:

20020198172, Dec 26, 2002

Filed:

Jul 30, 2002

Appl. No.:

10/207111

Inventors:

Bobby Sandage - Lexington MA, US
Glenn Cooper - Sudbury MA, US
Kenneth Locke - Littleton MA, US
Takashi Kiyoizumi - Wellesley MA, US

International Classification:

A61K031/7072

US Classification:

514/049000

Abstract:

The invention is directed to a method of treating a motor neuron disease or demyelinating disease, by the administration of citicoline to patients with a motor neuron disease or a demyelinating disease. The method is useful in the treatment of ALS and MS and maximizes the chances for a reduction, alleviation, or amelioration of ALS or MS symptoms in a patient. Combination treatment regimens are also disclosed along with compositions for use therewith.

US Patent:

54038510, Apr 4, 1995

Filed:

Apr 5, 1994

Appl. No.:

8/223352

Inventors:

Kay J. D'Orlando - Wayland MA
Kenneth W. Locke - Littleton MA
Emile M. Bellott - Beverly MA
Richard L. Gabriel - Swampscott MA
Michael D. Nohrden - Stow MA
Yesh P. Sachdeva - Concord MA
Salah A. Zahr - Acton MA
Emile Al-Farhan - West Roxbury MA
Subramaniam Krishnananthan - Waltham MA

Assignee:

Interneuron Pharmaceuticals, Inc. - Lexington MA

International Classification:

A61K 3142
A61K 3141
C07D27110
C07D20908

US Classification:

514364

Abstract:

This invention relates to novel substituted tryptamine and phenalkylamine and related compounds, pharmaceutical compositions thereof and methods of using said compounds and compositions for a number of pharmaceutical indications including (but not limited to): 1. central nervous system and psychiatric disorders (e. g. , sleep disorders, epilepsy and other convulsive disorders, anxiety, psychiatric diseases, neurodegenerative diseases, fever); 2. chronobiological-based disorders (e. g. , jet lag, delayed sleep syndrome, shift-work, seasonal affective disorder); 3. endocrine indications (e. g. , contraception and infertility, precocious puberty, premenstrual syndrome, hyperprolactinemia, growth hormone deficiency); 4. cancer and other proliferative diseases; 5. immune system disorders and conditions associated with senescence; 6.

US Patent:

58011609, Sep 1, 1998

Filed:

Mar 18, 1997

Appl. No.:

8/820244

Inventors:

Bobby Winston Sandage - Acton MA
Marc Fisher - Shrewsbury MA
Kenneth Walter Locke - Littleton MA

Assignee:

Interneuron Pharmaceuticals, Inc. - Lexington MA

International Classification:

A61K 3170

US Classification:

514 49

Abstract:

Methods and pharmaceutical compositions for reducing the extent of infarction, particularly cerebral infarction subsequent to cerebral ischemia.

US Patent:

58721088, Feb 16, 1999

Filed:

Feb 20, 1996

Appl. No.:

8/603102

Inventors:

Bobby W. Sandage - Lexington MA
Marc Fisher - Lexington MA
Kenneth W. Locke - Lexington MA

Assignee:

Interneuron Pharmaceuticals, Inc. - Lexington MA

International Classification:

A61K 3170

US Classification:

514 49

Abstract:

The invention is directed to a method of reducing the extent of infarction, particularly cerebral infarction subsequent to cerebral ischemia, by the administration of citicoline shortly after an ischemic episode and continuing daily treatment for up to about 30 days, preferably for at least about 6 weeks. The method is useful in the treatment of stroke and severe head trauma patients and maximizes the chances for a full or substantially full recovery of the patient.

US Patent:

58278320, Oct 27, 1998

Filed:

Mar 1, 1996

Appl. No.:

8/609448

Inventors:

Bobby W. Sandage - Acton MA
Marc Fisher - Shrewsbury MA
Kenneth W. Locke - Littleton MA

Assignee:

Interneuron Pharmaceuticals, Inc. - Lexington MA

International Classification:

A61K 3170

US Classification:

514 49

Abstract:

The invention is directed to a method of reducing the extent of infarction, particularly cerebral infarction subsequent to cerebral ischemia, by the administration of citicoline shortly after an ischemic episode and continuing daily treatment for up to about 30 days, preferably for at least about 6 weeks. The method is useful in the treatment of stroke and severe head trauma patients and maximizes the chances for a full or substantially full recovery of the patient. Combination treatment regimens are also disclosed along with compositions for use therewith.

US Patent:

52600912, Nov 9, 1993

Filed:

Oct 21, 1992

Appl. No.:

7/964328

Inventors:

Kenneth W. Locke - Burlington MA
Stuart Fielding - Morris Plains NJ

Assignee:

Interneuron Pharmaceuticals Inc. - Lexington MA

International Classification:

A23L 1237

US Classification:

426649

Abstract:

Compositions that are effective as salt substitutes and enhancers comprise novel mixtures of sodium chloride and derivatives of amiloride, indanyloxyacetic acid, or anthranilic acid. The present invention provides for a method of enhancing the saltiness of edible materials by the addition of the above-mentioned derivatives. The present invention further provides for a method of imparting saltiness to, or enhancing saltiness of, edible materials by the administration or use of the above-mentioned derivatives in lieu of the higher levels of sodium chloride that would be required if sodium chloride were being used alone.

US Patent:

55808786, Dec 3, 1996

Filed:

Jun 7, 1995

Appl. No.:

8/486788

Inventors:

Kay J. D'Orlando - Wayland MA
Kenneth W. Locke - Littleton MA
Emile M. Bellott - Beverly MA
Richard L. Gabriel - Swampscott MA
Michael D. Nohrden - Stow MA
Yesh P. Sachdeva - Concord MA
Salah A. Zahr - Acton MA
Emile Al-Farhan - West Roxbury MA
Subramaniam Krishnananthan - Waltham MA

Assignee:

Interneuron Pharmaceuticals, Inc. - Lexington MA

International Classification:

A61K 31405
C07D47106

US Classification:

514292

Abstract:

This invention relates to novel substituted tryptamine and phenalkylamine and related compounds, pharmaceutical compositions thereof and methods of using said compounds.